These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12236477)

  • 1. Proton pump inhibitors--differences emerge in hepatic metabolism.
    McColl KE; Kennerley P
    Dig Liver Dis; 2002 Jul; 34(7):461-7. PubMed ID: 12236477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    Robinson M
    Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.
    Thjodleifsson B
    Drugs Aging; 2002; 19(12):911-27. PubMed ID: 12495367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Blume H; Donath F; Warnke A; Schug BS
    Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
    Cianciolo G; Feliciangeli G; Comai G; Stefoni S
    Minerva Urol Nefrol; 2007 Jun; 59(2):207-15. PubMed ID: 17571057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors.
    Egan LJ; Murray JA
    Dig Dis; 2000; 18(2):58-63. PubMed ID: 11060468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.
    Ishizaki T; Horai Y
    Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():27-36. PubMed ID: 10491726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
    Sharara AI
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.
    Stedman CA; Barclay ML
    Aliment Pharmacol Ther; 2000 Aug; 14(8):963-78. PubMed ID: 10930890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion.
    Lindberg P; Keeling D; Fryklund J; Andersson T; Lundborg P; Carlsson E
    Aliment Pharmacol Ther; 2003 Feb; 17(4):481-8. PubMed ID: 12622756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
    Miyoshi M; Mizuno M; Ishiki K; Nagahara Y; Maga T; Torigoe T; Nasu J; Okada H; Yokota K; Oguma K; Tsuji T
    J Gastroenterol Hepatol; 2001 Jul; 16(7):723-8. PubMed ID: 11446878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.